Dates: November 6-9, 2025
Location: San Diego Convention Center, California, USA
Organizer: CTAD (Clinical Trials on Alzheimer's Disease)
Website: ctad-alzheimer.com
CTAD 2025 was held in San Diego, California, presenting the latest clinical trial results in Alzheimer's disease research. The conference is the premier venue for presenting Phase 2 and Phase 3 clinical trial data, bringing together academic researchers, pharmaceutical companies, and regulatory agencies.
CTAD 2025 featured extensive data on anti-amyloid monoclonal antibodies:
- Lecanemab (Leqembi) — CLARITY-AD long-term follow-up data
- Donanemab (Kisunla) — TRAILBLAZER-ALZ 2 extended outcomes
- Anti-amyloid next-generation antibodies — Novel binding profiles and safety data
- Combination approaches — Anti-amyloid with tau or neuroinflammation targets
Tau-targeted therapies were a major focus:
- Anti-tau antibodies — Multiple Phase 2/3 programs
- Tau aggregation inhibitors — Small molecule programs
- Tau PET imaging correlations with clinical outcomes
- Tau downstream effects — Synaptic function and neuronal loss
The integration of biomarkers into clinical trials was prominently featured:
- Blood-based biomarkers for patient selection and endpoint assessment
- p-tau217 as a surrogate endpoint
- Amyloid PET standardization and quantification
- Neurodegeneration markers (NfL, t-tau)
Updates from Alzheimer's prevention initiatives:
- Dominantly Inherited Alzheimer Network (DIAN) trials
- Alzheimer's Prevention Initiative (API) updates
- A4 Study (Anti-Amyloid in Asymptomatic Alzheimer's)
- Risk reduction trials in sporadic AD
Innovative approaches to clinical trial methodology:
- Platform trials for efficient drug testing
- Adaptive designs in late-stage trials
- Digital endpoints and remote monitoring
- Diversity in clinical trials strategies
- Phase 3 trial results from major pharmaceutical companies
- Novel therapeutic agent first-in-human data
- Regulatory pathway discussions
- "Lessons Learned from Anti-Amyloid Trials" — Optimizing future studies
- "Tau as a Therapeutic Target" — Current status and future directions
- "Biomarkers as Surrogate Endpoints" — Regulatory perspectives
- "Clinical Outcome Assessment" — Cognitive and functional measures
- Statistical Methods for Alzheimer's clinical trials
- Clinical Operations in diverse populations
- Data Sharing and collaborative analyses
CTAD 2025 featured presentations from leading pharmaceutical and biotechnology companies:
- Eisai/ Biogen — Leqembi development program
- Eli Lilly — Donanemab and other pipeline programs
- Roche/ Genentech — Anti-amyloid and anti-tau programs
- Johnson & Johnson — Neuroscience pipeline
- AbbVie — Neurodegeneration portfolio
- Axon Neuroscience — Tau vaccine program
Located in downtown San Diego, the convention center provides state-of-the-art facilities for clinical presentations and poster sessions.
San Diego is home to a thriving biotechnology community:
- UC San Diego — Leading Alzheimer's research center
- Scripps Research Institute — Drug discovery expertise
- Sanford Burnham Prebys — Neurobiology research
- Multiple biotechnology companies — Alzheimer's drug development
San Diego has established itself as a major center for Alzheimer's clinical research:
- Multiple memory clinics and research centers
- Strong academic-industry partnerships
- Diverse patient populations for clinical trials